Company Details
Zelos Therapeutics
100 Front Street Suite 1325, West Conshohocken, PA, 19428, United States
Overview
Zelos Therapeutics is developing a next-generation parathyroid hormone (PTH) analogue. The company plans to advance that candidate into clinical trials across four distinct indications. To support this development, Zelos raised $42.5 million in a Series B financing. The proceeds are earmarked to fund those clinical trials. No operating metrics (such as revenue or user figures) were reported in the article.
- Total raised
- $43M
- Funding rounds
- 1
- Latest round
- Series B
- Latest activity
- Oct 2024
Industries
- Health Care
- Medical
- Pharmaceutical
- Therapeutics
Recent funding
Series B
Oct 2024
$43M
Team
No current team members are available.